Overview

A Dose-finding Study of ASP4070

Status:
Completed
Trial end date:
2018-10-27
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Immunomic Therapeutics, Inc.
Treatments:
Vaccines